Skip to content

Corporate
- Pitch
- Mission
- CSR
- Team
Technology
Pipeline
Clinical trials
Newsroom
Partnerships

Home
Corporate
- Pitch
- Mission
- CSR
- Team
Technology
Pipeline
Clinical trials
Newsroom
Partnerships
Contact

C

covid-19 Non classé

1 min read

[Alerte actualité] Anticorps XAV19

Author Edouard Hueber
Published 5 mai 2020

30 avril 2020

Download the press release / Télécharger le communiqué

Related Posts

[Press Release] XENOTHERA recruits the first patient in the clinical trial of XON7, its new anti-cancer treatment

November 27, 2023. # Download our press release (english version) # Télécharger...

[Press Release] French biotech announces its therapeutic potential for oxygen-free patients

October 25, 2023. # Download our press release (english version) # Télécharger...

[Press Release] New hope for patients: XENOTHERA granted orphan drug designation (ODD ) from the FDA for LIS1 in the treatment of T-lymphomas.

September 12, 2023. # Download our press release (english version) # Télécharger...

Corporate
Technology
Pipeline

Clinical trials
Newsroom
Partnerships

Contact
Legal notice

XENOTHERA

21 rue La Nouë de Fer, 44200 Nantes, France

contact@xenothera.com

Media : xenothera@izsogood.co